Список литературы

1. American Academy of Ophthalmology Preferred Practice Patterns Committee. Preferred Practice Pattern(R) Guidelines. Comprehensive Adult Medical Eye Evaluation. San Francisco, CA: AAO (2005). Available at: http://www.aao.org/ppp.

2. Sobrin L., Seddon J.M. Nature and nurture-genes and environment-predict onset and progression of macular degeneration/Progress in retinal and eye research. - 2014. - Vol. 40. - P. 1 - 15.

3. Nita M. et al. Age-related macular degeneration in the aspect of chronic low-grade inflammation (pathophysiological parainflammation)/Mediators of inflammation. - 2014. DOI: 10.1155/2014/930671

4. Beatty S. et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration/Survey of ophthalmology. - 2000. - Vol. 45. N 2. - P. 115 - 134.

5. Nita M. et al. Age-related macular degeneration and changes in the extracellular matrix/Medical science monitor: international medical journal of experimental and clinical research. - 2014. - Vol. 20. - P. 1003.

6. Arya M. et al. Choriocapillaris changes in dry age-related macular degeneration and geographic atrophy: a review/Eye and Vision. - 2018. - Vol. 5. N 1. - P. 1 - 7.

7. Wong W.L. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis/The Lancet Global Health. - 2014. - Vol. 2. N 2. - P. 106 - 116.

8. Klein R. et al. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study/Ophthalmology. - 2002. - Vol. 109. N 10. - P. 1767 - 1779.

9. Нероев, В.В. Российское наблюдательное эпидемиологическое неинтервенционное исследование пациентов с влажной формой возрастной макулярной дегенерации/В.В. Нероев//Российский офтальмологический журнал. - 2011. - N 2. - С. 4 - 9.

10. Friedman D.S. et al. Prevalence of age-related macular degeneration in the United States/Arch ophthalmol. - 2004. - Vol. 122. N 4. - P. 564 - 572.

11. Velilla S. et al. Smoking and age-related macular degeneration: review and update/Journal of ophthalmology. - 2013. DOI: 10.1155/2013/895147

12. Rudnicka A.R. et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis/Ophthalmology. - 2012. - Vol. 119. N 3. - P. 571 - 580.

13. Ratnapriya R., Chew E.Y. Age-related macular degeneration-clinical review and genetics update/Clinical genetics. - 2013. - Vol. 84. N 2. - P. 160 - 166.

14. Chakravarthy U. et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis/BMC ophthalmology. - 2010. - Vol. 10. N 1. - P. 31.

15. Erke M.G. et al. Cardiovascular risk factors associated with age-related macular degeneration: the Tromso Study/Acta ophthalmologica. - 2014. - Vol. 92. N 7. - P. 662 - 669.

16. Tomany S.C. et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents/Ophthalmology. - 2004. - Vol. 111. N 7. - P. 1280 - 1287.

17. Офтальмология: национальное руководство/ред. С.Э. Аветисов, Е.А. Егоров, Л.К. Мошетова, В.В. Нероев, Х.П. Тахчиди. - 2ое изд - М.: ГЭОТАР-Медиа, 2018. - 904с. - (Серия "Национальное руководство")

18. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8/Archives of ophthalmology. - 2001. - Vol. 119. N 10. - P. 1417.

19. Garcia-Layana A. et al. Early and intermediate age-related macular degeneration: update and clinical review/Clinical Interventions in Aging. - 2017. - Vol. 12. - P. 1579.

20. Нероев В.В., Астахов Ю.С., Коротких С.А., Бобыкин Е.В., Зайцева О.В., Лисочкина А.Б., Бровкина А.Ф., Будзинская М.В., Гацу М.В., Григорьева Н.Н., Измайлов А.С., Карлова Е.В., Ковалевская М.А., Нечипоренко П.А., Панова И.Е., Рябцева А.А., Симонова С.В., Тульцева С.Н., Фурсова А.Ж., Шадричев Ф.Е., Шишкин М.М., Харлампиди М.П. Протокол выполнения интравитреального введения лекарственных препаратов. Консенсус Экспертного совета по заболеваниям сетчатки и зрительного нерва Общероссийской общественной организации "Ассоциация врачей-офтальмологов". Вестник офтальмологии. 2020; 136(6): 251 - 263. https://doi.org/10.17116/oftalma2020136062251.

21. СанПиН 2.1.3.2630-10 "Санитарно-эпидемиологические требования к организациям, осуществляющим медицинскую деятельность".

22. Приказ Министерства здравоохранения и социального развития РФ от 29 декабря 2008 г. N 786н "О порядке формирования и утверждении государственного задания на оказание в 2009 году высокотехнологичной медицинской помощи гражданам Российской Федерации за счет ассигнований федерального бюджета" (с изменениями и дополнениями).

23. Управление плановой госпитализацией в многопрофильной больнице. Методические рекомендации N 2001/144: (утв. Минздравом РФ 09.11.2001).

24. Grassmann F. et al. Deep Learning Algorithm for Prediction of Age-Related Eye Disease Study Severity Scale for Age-Related Macular Degeneration from Color Fundus Photography/Ophthalmology. - 2018. - Vol. 125. N 9. - P. 1410 - 1420.

25. Ly A. et al. Fundus autofluorescence in age-related macular degeneration/Optometry and Vision Science. - 2017. - Vol. 94. N 2. - P. 246.

26. Castillo M.M. et al. Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review/Ophthalmology. - 2015. - Vol. 122. N 2. - P. 399 - 406.

27. Wilde C. et al. The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography. Eye (Lond). - 2015. - Vol. 29. N 5. - P. 602 - 609.

28. Roisman L., Goldhardt R. OCT Angiography: an upcoming non-invasive tool for diagnosis of age-related macular degeneration/Current ophthalmology reports. - 2017. - Vol. 5. N 2. - P. 136 - 140.

29. Ультразвуковые исследования в офтальмологии: руководство для врачей/ред. В.В. Нероев, Т.Н. Киселева. - 1-е издание. - М.: Издательство ИКАР, 2019. - 322 с.

30. Зуева, М.В. Электроретинография в диагностике и мониторинге лечения неоваскулярной возрастной макулярной дегенерации/И.В. Цапенко, М.В. Рябина, М.И. Гринченко, Н.В. Нероева//Вестник Офтальмологии. - 2009. - Т. 125. N 4. - С. 54 - 58.

31. Chapman N.A. et al. Role of diet and food intake in age-related macular degeneration: a systematic review/Clinical & experimental ophthalmology. - 2019. - Vol. 47. N 1. - P. 106 - 127.

32. Amirul Islam F.M. et al. Dietary patterns and their associations with age-related macular degeneration: the Melbourne collaborative cohort study/Ophthalmology. - 2014. - Vol. 121. N 7. - P. 1428 - 1434.

33. Zajac-Pytrus H.M. et al. The dry form of age-related macular degeneration (AMD): the current concepts of pathogenesis and prospects for treatment/Adv Clin Exp Med - 2015. - Vol. 24. N 6. - P. 1099 - 1104.

34. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials/Archives of ophthalmology. - 1991. - Vol. 109. - P. 1109 - 1114.

35. TAP Study Group. Improvement after verteporfin therapy/Archives of ophthalmology. - 2003. - Vol. 121. - P. 415.

36. Guymer RH, Brassington KH, Dimitrov P, Makeyeva G, Plunkett M, Xia W, Chauhan D, Vingrys A, Luu CD. Nanosecond-laser application in intermediate AMD: 12-month results of fundus appearance and macular function. Clin Experiment Ophthalmol 2013 11 Nov 2013. doi: 10.1111/ceo.12247

37. Nguyen C.L. et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials/BMC Ophthalmology - 2018. - Vol. 30 N 18(1). - P. 130.

38. Dugel P.U., et al. HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration/Ophthalmology - 2021. Vol. 128. N 1. - P. 89 - 99.

39. Heier J.S., et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials/The Lancet - 2022. - Vol. 399. N 10326. - P. 729 - 740. DOI:https://doi.org/10.1016/S0140-6736(22) 00010-1

40. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration/New England Journal of Medicine - 2011. - Vol. 364. N 20. - P. 1897 - 1908.

41. Sarwar S. et al. Aflibercept for neovascular age-related macular degeneration./Cochrane Database Syst Rev. - 2016. DOI: 10.1002/14651858.CD011346.pub2

42. Ohji M et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: A Randomized Controlled Trial/Adv Ther. - 2020. - Vol. 37. N 3. - P. 1173 - 1187. DOI: 10.1007/s12325-020-01236-x

43. Saharinen P., et al. Therapeutic targeting of the angiopoietin-TIE pathway/Nat Rev Drug Discov - 2017. - Vol. 16. - P. 635 - 661. DOI:https://doi.org/10.1038/nrd.2016.278

44. Sahni J., et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration. The AVENUE Phase 2 Randomized Clinical Trial/JAMA Ophthalmol. - 2020. - Vol. 138, N 9. - P. 955 - 963. DOI: 10.1001/jamaophthalmol.2020.2685

45. Бойко Э.В., Даниличев В.Ф., Сажин Т.Г. и др. Методы клинического применения рекомбинантной проурокиназы в офтальмологической практике//РМЖ. Клиническая офтальмология. - 2017. - N 2. - С. 118 - 129.

46. Forooghian F. et al. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept./Canadian Journal of Ophthalmology - 2017. - Vol. 52. N 6. - P. 616 - 619.